Biosite and FivePrime Announce Antibody Collaboration
News Feb 22, 2006
Under the collaboration, FivePrime will provide Biosite access to selected functional disease targets for use in developing diagnostics.
In exchange, Biosite will provide FivePrime with Omniclonal® antibodies for selected targets to accelerate FivePrime's therapeutic research efforts.
Biosite's proprietary antibody development process is designed to generate diverse libraries of Omniclonal antibodies with high affinity and low cross-reactivity.
"FivePrime's comprehensive protein discovery program is providing a wealth of valuable therapeutic and diagnostic candidates," commented Gail Maderis, FivePrime's president and chief executive officer.
"This collaboration is a strategic win for both companies. It expands Biosite's portfolio of novel diagnostic targets and provides high quality antibodies to accelerate development of FivePrime's therapeutic pipeline."
"Biosite's discovery efforts are focused on developing a broad and diverse portfolio of novel diagnostics for diseases that lack rapid, accurate diagnostic methods," said Gunars Valkirs, Ph.D., senior vice president Biosite Discovery.
"FivePrime is a recognized industry leader in the discovery of novel targets, so we are pleased to begin this collaboration."
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE
Ataxin Links Long Term-Memory and NeurodegenerationNews
Scientists have just discovered that a small region of a cellular protein that helps long-term memories form also drives the neurodegeneration seen in motor neuron disease (MND)READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018